sunni sky biopharma cloud
solut initi buy pt
larg tam expand product line impecc
think broad saas-bas cloud solut make preemin
vendor life scienc compani market leader commerci
offer growth success expand presenc
clinic solut growth move vertic
outsid life scienc think pois top line
growth next year surpass bil revenu way bil
attract larg expand solid technolog
platform product develop consist financi execut
see strong macro tailwind biopharma compani increas
invest technolog drive effici product
success gain market leadership commerci solut --
expand presenc clinic develop solut
estim posit captur least current
address time today believ captur
impli earli stage long growth trajectori
veeva cloud-bas product built bottom allow unifi
experi compat across product suit continu
expand predominantli organ basi intern effort
think veeva wide penetr creat moat around accept
familiar product suit help drive new client platform
view reinforc veeva preemin softwar provid life
veeva step outsid life scienc vault qualityon earli
stage estim repres upward
price pt base weight scenario impli
ev/fcf multipl analysi support peer
multipl well stand alon dcf analysi reflect believ
long runway top-lin growth superior ebitda margin
catalyst acceler adopt exist vault product success
introduct new product expans new market vertic
risk manag expand margin remain high growth compani
increas competit medidata iqvia entranc new vertic
tr target
strh consenu figur restat
except consensu ebitda figur
adjust one time tax benefit
tabl content
summari scenario
sourc commerci cloud growth sourc overal revenu
invest highlight sourc demand/growth
sourc increment revenu growth macro industri survey
survey data demonstr industri pain point address
heatmap identifi sourc growth vault client growth
sourc subscript growth client concentr
deeper look veeva product
 trial workflow chart veeva product overlay clinic app
invest highlight product client penetr
heatmap competit landscap
heatmap major client vs top
drug pipelin drug approv
top biopharma recent project
invest highlight entranc new
page
tabl content
revenu growth margin expans trend
geograph revenu mix oper margin
oper margin expenditur
sale market trend assess sale effici vs
free cash flow convers assess equiti comp vs cfo
analysi calcul
broad financi overview outlook analysi histor guidanc vs
analysi beat rais price target scenario
summari zinc ahead acquisit agreement
manag board
page
believ life scienc industri still remain earli year see biopharma
shift budget toward new technology-ori solut drive drug innov
see remain well posit benefit trend alreadi
sizeabl presenc continu gain market share
deepen client relationship greater enterpris use broader product adopt
averag product per client continu grow penetr exist client
whether perenni commerci cloud custom adopt vault offer and/or new
product add-on commerci cloud vault addit broader adopt product
seat continu current hand client full organ penetr
new custom win view trust partner life scienc industri expect
momentum client expans continu market share grab opportun exist
displac legaci system within establish biopharma compani well
new client win nascent biotech firm notabl biotech fund environ
remain ripe see also point veev establish cro-focus sale forc
indic larg opportun space thu far scratch
widen moat prolifer quantiti complex geograph divers
associ rise level manag drug commerci process view
veeva fulli integr cloud platform increasingli entrench toolkit use pharma
biotech compani view momentum deepen client relationship
persist continu innov new product top exist commerci cloud
vault offer reinforc veev continu product introduct date
expect increas spend percentag revenu next sever year
strong manag team proven track record co-found bring industri
expertis co-found ceo peter gassner bring experi former vice-president
technolog buy rate cover terri tillman co-
founder presid matt wallach help build oracle-own nr siebel
life scienc practic track record also success compani
seen robust organ revenu growth simultan improv margin robust free
entri new vertic although juri may still scope opportun
resourc requir gain meaning footprint vertic outsid life
scienc initi adopt vault qualiti one suggest well posit grow sale
segment initi estim suggest qualiti one could opportun
estim increas veev
page
margin compress risk transit new vertic requir up-front
invest prospect revenu growth nascent unproven entri
new vertic may creat neg increment margin initi believ
requir greater spend compet incumb player guarante
effort reward materi gain market share correspond revenu
matur client penetr commerci cloud shift growth prospect vault
veev solut use top pharma compani revenu growth
commerci cloud matur like slip compound-annual-growth-rate mid- low- doubl digit
see top-line growth hold vault need remain primari growth
engin come year
veeva control compani materi constrain sharehold activ veeva
two class share structur insid control vote share would highli
limit strateg decis insid furthermor veeva stagger board structur
would limit take-over control initi
uncertain futur term partnership veeva
associ applic develop platform
agreement
provid host data center portion applic
addit platform function arrang pay salesforc fee
current arrang expir sept creat potenti risk beyond date
term renew agreement could subject chang
slow growth may place valuat multipl risk share trade premium
broader softwar peer group ntm ev/sal vs growth
peer growth peer group ntm ev/ebitda vs
growth peer growth peer believ premium
gener industri leadership superior growth lead sale effici margin expans
robust free cash flow gener could variabl measur
note trade estim ntm ev/fcf multipl bracket
ntm ev/fcf median multipl mean multipl growth
peer trade discount ntm ev/fcf growth peer
think there risk multipl compress could come misstep
growth stori and/or deflat valuat multipl market assign softwar
outstand legal challeng present j-factor risk possibl form monetari damag
constraint growth prospect certain product see two notabl legal
disput mdso iqvia im busi
page
blend valuat scenario deriv price pt
weight averag scenario analysi support dcf peer multipl
base appli probabl low-cas pt ev/fcf mid-
case pt ev/fcf high-cas pt ev/fcf
case assum year compound-annual-growth-rate believ would clear billion
sale target set manag ascrib scenario probabl given
view veev momentum posit clear hurdl rate
mid case assum year compound-annual-growth-rate believ like trajectori
expect revenu mix shift continu favor subscript growth ascrib
scenario probabl given view veev momentum strong given consecut
quarter rais guidanc beat rais solid histori beat rais
high case assum year compound-annual-growth-rate believ achiev greater
client penetr broader adopt exist recent launch upcom product
within new exist vertic could contribut acceler subscript
revenu ascrib scenario probabl given veeva consist histori
exceed expect success fast adopt organ creat product
page
comp support ev/fcf multipl appli veeva high-teen grower compound-annual-growth-rate basi
within model think grower applic peer group trade
averag ntm ev/fcf median pt impli multipl
estim believ warrant given view long runway high-teen top-line
growth peer-high ebitda margin
support ev/fcf valuat via dcf model contempl ten
year compound-annual-growth-rate oper margin approach ebitda convers rate
page
sale growthev/salesev/ebitdaev/fcfnametickerstock price group group sale growthev/salesev/ebitdaev/fcfnametickerstock price group group sale growthev/salesev/ebitdaev/fcfnametickerstock price group group compani report guidanc strh estim factset cash assumptionsdcf increment y/i capdil wasointrins sourc compani data strh research million except per share data adj tax benefit
compani overview veeva found predominantli provid saas-bas cloud
solut target life scienc industri product servic primarili design
support sale market research develop effort life scienc client
start serv custom employ peopl although
serv largest pharmaceut biotechnolog custom global one client
account revenu sinc go public
page
veeva believ feasibl target captur address
commerci cloud vault impli potenti annual revenu given
backdrop estim revenu suggest growth remain earli inning
commerci cloud includ core offer well add-on
network data sit accord veeva gener figur
also includ certain sale market product veeva deliv
market suggest veeva could potenti see upsid sale growth new
product introduct segment matur longer term growth profil rang
mid- singl low- doubl digit see global pharma
rep use veeva platform see littl opportun addit share gain
page
 cloudvaultvault qualiti revenuequantifi veeva address marketsourc strhresearch penetrationpharma rep use veevaglob pharma rep veevasourc strh research total rep global veeva system inc
given grab market expect cross-sel predomin contributor
long term revenu growth think year half growth come
addit seat half cross sell add-on product expect cross sell add-on
fuel lion share longer term growth commerci cloud
matur commerci cloud shift growth burden veeva vault predomin
vault main driver growth mani product recent
introduc along segment largest address tam accord veeva
figur target clinic regulatori qualiti
product clinic largest contributor balanc account
commerci within clinic etmf electron master file edc electron data
captur clinic trial manag softwar andannounc yet releas
esourc safeti product esourc applic directli feed edc without
need transcrib collect trial data safeti focus pharmacovigil
page
commerci cloud growthseatscross sell add-onssourc strh research total revenu growth commerci cloud vs vault sourc strh research estim beyond millionssourc strh research estim beyond millionssourc strh research estim beyond millionssourc strh research estim beyond
invest highlight challeng within life scienc fuel demand veev solut
also increas quantiti address differ segment within life scienc
although core product reach satur within instal base believ
remain ideal posit benefit continu adopt cloud-bas
idc futurescap world-wide industri predict idc extrapol
predict sever trend believ continu tailwind
idc see enterpris infrastructur softwar spend cloud-
client challeng reveal logic behind cadenc product veeva releas
see think common tech challeng life scienc compani like integr
across applic eas use data collect collabor concern undoubtedli
result tradit market servic varieti point solut think
veeva posit disrupt industri innov solv mani problem
area pain industri
accord veeva unifi clinic oper annual cro report
cro respond report need unifi clinic
applic includ edc etmf report
integr multipl applic biggest challeng face
point success veeva matur vault etmf offer gateway product
help veeva time synergist penetr exist client newli debut
 edc solut announc safeti esourc product line alreadi appear
case sign client either alreadi vault etmf purchas vault
etmf alongsid vault subscript
page
increment revenuevaultcommerci cloudsourc strh research sourc strh research estim strh given limit avail disclosur
key differenti veeva platform view built ground
singl technolog platform stack believ lower difficulti surround
softwar upgrad incorpor new featur compar competitor typic
unifi multipl system brought
veeva recent introduct edc appear address clear pain point industri
accord survey uniqu compani domicil averag
year experi clinic data manag median year conduct may-
juli tuft center studi drug develop respond
experi challeng load data primari edc
respond load challeng identifi integr issu
caus load challeng identifi edc system limit obstacl
believ veeva full integr cloud-bas platform potenti directli address
data load challeng respond survey could
repres opportun broader edc market said edc system tend
sticki difficult replac suggest us meaning adopt beyond
year mark like gradual undertak given gener fragment grow
market mani point solut invest highlight think veeva could grow edc
busi without necesset materi market share grab largest edc provid mdso
page
challeng clinic applicationscrosponsorsourc unifi clincial oper survey annual cro report strh research respondentsq bigest chllaneg nay organ face util clinic applicaiton identifi edc etmf etc select load challeng sourc tuft center studyof drug develop strhresearchintegrationissuesedc system limitationstechnicaldemand support staffoth veeva system inc
vault product suit posit drive growth time base expect gradual
penetr client base etmf wide adopt vault product
mark histor second best sale quarter though still signific driver revenu
growth time expect increment revenu contribut shift toward
product expect adopt stagger instanc think adopt
faster edc purchas trial-by-tri basi edc much
entrench product multipl data trial attach
veeva client base grew compound annual growth rate sinc
revenu grew time period revenu leverag come client
quantiti size penetr driven seat product per client suggest
tabl veeva vault primari revenu driver benefit
nascent product line also carri higher veeva core offer
page
sourc vault growth timelin heatmap legend noneearli ramp yrsvault etmfvault qualityvault commerci suitevault rim suitevault qualiti onevault esourcevault safetyvault ctmsvault edcunannounc product sourc strh research growth penetrationvaulttot sourc strh research total account vault client overlap
exist client continu main sourc engin growth exist client
account lion share observ growth last year recent
exist client account growth averag last
year veeva recogn approxim growth come exist client
client concentr shrink suggest growth burden exist
client wide distribut toward smb client life scienc industri
larg portion trial commerci effort driven small number larg pharma
firm recent result veeva deriv revenu top client
although veeva client end top account
revenu notabl decreas last year
vault qualityon veeva foray vertic outsid life scienc qualityon
repurpos vault product suit target qualiti solut new vertic target industri
includ chemic cpg cosmet nutraceut food beverag industri product
oil ga veeva demonstr earli success interest chemic space
qualityon focu manufactur firm within vertic manufactur
account annual domest revenu manufactur
revenu veeva alloc dedic sale strategi servic team vertic
well small develop team focu specif featur qualityon alreadi
demonstr success earli adopt client end expect ramp
 america europ year
page
subscriptiongrowthexist clientsnew client sub growth exist clientssourc strh research revenu top clientssourc strh research total revenu custom exceed
deeper look veeva suit product
compris custom relationship manag
applic facilit sale market product sold pharma biotech
compani applic commerci cloud expand time includ
variou abil manag life-cycle sale market initi
part commerci cloud veeva also custom product depositori veeva
network record healthcar profession organ product
opendata gener inform demograph licens specialti affili
profil need drive custom engag complianc client veeva also offer
opinion leader kol data servic analyz gener inform
veeva nitro new commerci data warehous commerci cloud umbrella nitro
seek elimin custom data wareh facilit unif client data
variou sourc prescript sale formulari claim data analyt readi
alreadi avail japan roll america end year see
improv veeva reach within exist commerci cloud expect impact
revenu felt beyond
page
cloud customersaverag commerci cloud product per customersourc strh research veeva system inc
although veeva initi built around platform focus drive post-
approv commerci effort veeva fastest grow segment largest address tam
base veeva vault whose solut focus life scienc drug develop
process map main system involv throughout drug trial
offer within veeva vault target demand applic use manag
page
start-upinvestigatorgr pmtecoartsmctmssafetyetmfedcappl use manag clinic studiessourc unifi clincial oper survey annual cro report strh research respond product organ util applic develop third-parti vendor manag clinic studi ye indicatewhich arecurr use
veeva vault cloud-bas enterpris content manag platform offer busi
applic sale market function includ clinic regulatori qualiti
vault design central repositori content- data- manag client
support multipl applic enabl streamlin process
vault clinic support clinic trial document vault etmf patient enrol
electron data convers electron data captur edc introduc
current earli phase adopt addit esourc function anticip
enabl electron captur site data collect elimin cost time
error transcrib collect trial site data also enabl real-tim site
collabor across trial site sponsor oct vault clinic
top custom custom overal
vault rim support regulatori manag product content life-cycle
includ registr submiss archiv publish veeva estim
address tam product suit octob vault rim
top custom custom overal
vault qualiti qualiti manag tool support creation
manag process control octob vault qualiti
top custom custom overal recent veeva repurpos
offer sell vertic spin product name vault qualiti one
earli interest adopt come chemic compani
vault medcomm act sourc distribut valid medic content across
channel geographi life scienc compani may use medcomm verbal
and/or written commun healthcar profession patient answer
vault commerci octob vault commerci top
custom custom overal organ custom way
zinc ahead acquisit
vault safeti recent announc product target safeti
pharmacovigil estim similar size regulatori
market accord five specif product expect underpin product
report safeti letter manag signal detect avail vault
safeti expect
page
partnership arrang enabl better integr partner solut
veeva offer entail econom agreement instanc partnership
clinic privat allow veeva suit product better integr clinic rtsm
random trial suppli manag softwar prancer similarli partnership
product offer like data analyt provid third parti partner like qlik privat
sumo logic privat integr veeva offer without econom compon
veeva consist expand product line predominantli organ fashion non-
comprehens tabl track highlight grow product suit
believ major addit could drive longer term growth roll year
edc well announc upcom safeti esourc product
page
customersavg vault product persourc strh researchsourc strh research veeva system inc
invest highlight veeva oper fragment market veeva consolid cloud-bas
platform ever broaden suit product gravit client fuel growth see
veeva first servic life scienc vertic alreadi one broadest suit
product offer among competitor demonstr non-comprehens heat
map competitor product veeva one broadest offer industri
recent product may take sever year meaning contribut
revenu growth think veeva prove effect develop market product
organ alreadi competit space commerci side view iqvia asset
previous imss acquisit cegedim primari competitor commerci cloud
strh disclosur product competitor heat map best guess use publicli disclos avail inform could
